Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

BACKGROUND: Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. While most MDR/RR-TB patients do not receive treatment, many who do are treated for 18 months or more. A shorter all-o...

Descripción completa

Detalles Bibliográficos
Autores principales: Guglielmetti, L., Ardizzoni, E., Atger, M., Baudin, E., Berikova, E., Bonnet, M., Chang, E., Cloez, S., Coit, J. M., Cox, V., de Jong, B. C., Delifer, C., Do, J. M., Tozzi, D. Dos Santos, Ducher, V., Ferlazzo, G., Gouillou, M., Khan, A., Khan, U., Lachenal, N., LaHood, A. N., Lecca, L., Mazmanian, M., McIlleron, H., Moschioni, M., O’Brien, K., Okunbor, O., Oyewusi, L., Panda, S., Patil, S. B., Phillips, P. P. J., Pichon, L., Rupasinghe, P., Rich, M. L., Saluhuddin, N., Seung, K. J., Tamirat, M., Trippa, L., Cellamare, M., Velásquez, G. E., Wasserman, S., Zimetbaum, P. J., Varaine, F., Mitnick, C. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465691/
https://www.ncbi.nlm.nih.gov/pubmed/34563240
http://dx.doi.org/10.1186/s13063-021-05491-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465691/
https://www.ncbi.nlm.nih.gov/pubmed/34563240
http://dx.doi.org/10.1186/s13063-021-05491-3

Ejemplares similares